182 related articles for article (PubMed ID: 37591933)
1. Programmable multispecific DNA-origami-based T-cell engagers.
Wagenbauer KF; Pham N; Gottschlich A; Kick B; Kozina V; Frank C; Trninic D; Stömmer P; Grünmeier R; Carlini E; Tsiverioti CA; Kobold S; Funke JJ; Dietz H
Nat Nanotechnol; 2023 Nov; 18(11):1319-1326. PubMed ID: 37591933
[TBL] [Abstract][Full Text] [Related]
2. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
3. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
[TBL] [Abstract][Full Text] [Related]
4. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases.
Rolin C; Zimmer J; Seguin-Devaux C
Cell Mol Immunol; 2024 May; ():. PubMed ID: 38789528
[TBL] [Abstract][Full Text] [Related]
5. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
6. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
7. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
8. DNA-Mediated Assembly of Multispecific Antibodies for T Cell Engaging and Tumor Killing.
Pan L; Cao C; Run C; Zhou L; Chou JJ
Adv Sci (Weinh); 2020 Jan; 7(2):1900973. PubMed ID: 31993277
[TBL] [Abstract][Full Text] [Related]
9. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
11. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
12. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma.
Singh K; Hotchkiss KM; Mohan AA; Reedy JL; Sampson JH; Khasraw M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795007
[TBL] [Abstract][Full Text] [Related]
13. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
[TBL] [Abstract][Full Text] [Related]
14. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
15. An Fc Binding Peptide-Based Facile and Versatile Build Platform for Multispecific Antibodies.
Xue F; Yao H; Cui L; Huang Y; Shao C; Shen N; Hu J; Tang Z; Chen X
Nano Lett; 2023 May; 23(10):4191-4200. PubMed ID: 37186944
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.
Alhallak K; Sun J; Wasden K; Guenthner N; O'Neal J; Muz B; King J; Kohnen D; Vij R; Achilefu S; DiPersio JF; Azab AK
Leukemia; 2021 Aug; 35(8):2346-2357. PubMed ID: 33479469
[TBL] [Abstract][Full Text] [Related]
17. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
18. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
19. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
20. Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.
Dickopf S; Buldun C; Vasic V; Georges G; Hage C; Mayer K; Forster M; Wessels U; Stubenrauch KG; Benz J; Ehler A; Lauer ME; Ringler P; Kobold S; Endres S; Klein C; Brinkmann U
Biol Chem; 2022 Apr; 403(5-6):495-508. PubMed ID: 35073465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
